FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2038992287> ?p ?o ?g. }

• W2038992287 endingPage "981" @default.
• W2038992287 startingPage "970" @default.
• W2038992287 abstract "Abstract Objective To compare the efficacy, safety, and tolerability of 6 dosages of oral tofacitinib (CP‐690,550) with placebo for the treatment of active rheumatoid arthritis (RA) in patients receiving a stable background regimen of methotrexate (MTX) who have an inadequate response to MTX monotherapy. Methods In this 24‐week, double‐blind, phase IIb study, patients with active RA (n = 507) were randomized to receive placebo or tofacitinib (20 mg/day, 1 mg twice daily, 3 mg twice daily, 5 mg twice daily, 10 mg twice daily, or 15 mg twice daily). All patients continued to receive a stable dosage of MTX. The primary end point was the American College of Rheumatology 20% improvement criteria (ACR20) response rate at week 12. Results At week 12, ACR20 response rates for patients receiving all tofacitinib dosages ≥3 mg twice daily (52.9% for 3 mg twice daily, 50.7% for 5 mg twice daily, 58.1% for 10 mg twice daily, 56.0% for 15 mg twice daily, and 53.8% for 20 mg/day) were significantly ( P ≤ 0.05) greater than those for placebo (33.3%). Improvements were sustained at week 24 for the ACR20, ACR50, and ACR70 responses, scores for the Health Assessment Questionnaire disability index, the 3‐variable Disease Activity Score in 28 joints using the C‐reactive protein level (DAS28‐CRP), and a 3‐variable DAS28‐CRP of <2.6. The most common treatment‐emergent adverse events occurring in >10% of patients in any tofacitinib group were diarrhea, upper respiratory tract infection, and headache; 21 patients (4.1%) experienced serious adverse events. Sporadic increases in transaminase levels, increases in cholesterol and serum creatinine levels, and decreases in neutrophil and hemoglobin levels were observed. Conclusion In patients with active RA in whom the response to MTX has been inadequate, the addition of tofacitinib at a dosage ≥3 mg twice daily showed sustained efficacy and a manageable safety profile over 24 weeks." @default.
• W2038992287 created "2016-06-24" @default.
• W2038992287 creator A5006565253 @default.
• W2038992287 creator A5014147030 @default.
• W2038992287 creator A5017734958 @default.
• W2038992287 creator A5029796262 @default.
• W2038992287 creator A5034581240 @default.
• W2038992287 creator A5040449706 @default.
• W2038992287 creator A5053704561 @default.
• W2038992287 creator A5057538503 @default.
• W2038992287 creator A5064863811 @default.
• W2038992287 creator A5067220142 @default.
• W2038992287 creator A5071926023 @default.
• W2038992287 creator A5081089231 @default.
• W2038992287 date "2012-03-27" @default.
• W2038992287 modified "2023-10-16" @default.
• W2038992287 title "A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone" @default.
• W2038992287 cites W1979925150 @default.
• W2038992287 cites W1985004174 @default.
• W2038992287 cites W1990105300 @default.
• W2038992287 cites W2033299724 @default.
• W2038992287 cites W2061785558 @default.
• W2038992287 cites W2098706915 @default.
• W2038992287 cites W2101217991 @default.
• W2038992287 cites W2110177517 @default.
• W2038992287 cites W2149189075 @default.
• W2038992287 cites W2151734278 @default.
• W2038992287 cites W2152348310 @default.
• W2038992287 cites W2159106700 @default.
• W2038992287 doi "https://doi.org/10.1002/art.33419" @default.
• W2038992287 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22006202" @default.
• W2038992287 hasPublicationYear "2012" @default.
• W2038992287 type Work @default.
• W2038992287 sameAs 2038992287 @default.
• W2038992287 citedByCount "299" @default.
• W2038992287 countsByYear W20389922872012 @default.
• W2038992287 countsByYear W20389922872013 @default.
• W2038992287 countsByYear W20389922872014 @default.
• W2038992287 countsByYear W20389922872015 @default.
• W2038992287 countsByYear W20389922872016 @default.
• W2038992287 countsByYear W20389922872017 @default.
• W2038992287 countsByYear W20389922872018 @default.
• W2038992287 countsByYear W20389922872019 @default.
• W2038992287 countsByYear W20389922872020 @default.
• W2038992287 countsByYear W20389922872021 @default.
• W2038992287 countsByYear W20389922872022 @default.
• W2038992287 countsByYear W20389922872023 @default.
• W2038992287 crossrefType "journal-article" @default.
• W2038992287 hasAuthorship W2038992287A5006565253 @default.
• W2038992287 hasAuthorship W2038992287A5014147030 @default.
• W2038992287 hasAuthorship W2038992287A5017734958 @default.
• W2038992287 hasAuthorship W2038992287A5029796262 @default.
• W2038992287 hasAuthorship W2038992287A5034581240 @default.
• W2038992287 hasAuthorship W2038992287A5040449706 @default.
• W2038992287 hasAuthorship W2038992287A5053704561 @default.
• W2038992287 hasAuthorship W2038992287A5057538503 @default.
• W2038992287 hasAuthorship W2038992287A5064863811 @default.
• W2038992287 hasAuthorship W2038992287A5067220142 @default.
• W2038992287 hasAuthorship W2038992287A5071926023 @default.
• W2038992287 hasAuthorship W2038992287A5081089231 @default.
• W2038992287 hasConcept C126322002 @default.
• W2038992287 hasConcept C142724271 @default.
• W2038992287 hasConcept C162156334 @default.
• W2038992287 hasConcept C197934379 @default.
• W2038992287 hasConcept C198451711 @default.
• W2038992287 hasConcept C204787440 @default.
• W2038992287 hasConcept C27081682 @default.
• W2038992287 hasConcept C2776233030 @default.
• W2038992287 hasConcept C2776312127 @default.
• W2038992287 hasConcept C2777575956 @default.
• W2038992287 hasConcept C2778375690 @default.
• W2038992287 hasConcept C2778886723 @default.
• W2038992287 hasConcept C2781059491 @default.
• W2038992287 hasConcept C2781413609 @default.
• W2038992287 hasConcept C2991744798 @default.
• W2038992287 hasConcept C71924100 @default.
• W2038992287 hasConcept C90924648 @default.
• W2038992287 hasConceptScore W2038992287C126322002 @default.
• W2038992287 hasConceptScore W2038992287C142724271 @default.
• W2038992287 hasConceptScore W2038992287C162156334 @default.
• W2038992287 hasConceptScore W2038992287C197934379 @default.
• W2038992287 hasConceptScore W2038992287C198451711 @default.
• W2038992287 hasConceptScore W2038992287C204787440 @default.
• W2038992287 hasConceptScore W2038992287C27081682 @default.
• W2038992287 hasConceptScore W2038992287C2776233030 @default.
• W2038992287 hasConceptScore W2038992287C2776312127 @default.
• W2038992287 hasConceptScore W2038992287C2777575956 @default.
• W2038992287 hasConceptScore W2038992287C2778375690 @default.
• W2038992287 hasConceptScore W2038992287C2778886723 @default.
• W2038992287 hasConceptScore W2038992287C2781059491 @default.
• W2038992287 hasConceptScore W2038992287C2781413609 @default.
• W2038992287 hasConceptScore W2038992287C2991744798 @default.
• W2038992287 hasConceptScore W2038992287C71924100 @default.
• W2038992287 hasConceptScore W2038992287C90924648 @default.
• W2038992287 hasIssue "4" @default.
• W2038992287 hasLocation W20389922871 @default.
• W2038992287 hasLocation W20389922872 @default.
• W2038992287 hasOpenAccess W2038992287 @default.

• next